| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V Dev, J Raniwall. Quetiapine: a review of its safety in the management of schizophrenia. Drug safety. vol 23. issue 4. 2001-02-22. PMID:11051217. |
quetiapine, a dibenzothiazepine derivative, is a atypical antipsychotic which has greater in vitro binding affinity for serotonin 5-ht2 receptors than for dopamine d2 receptors. |
2001-02-22 |
2023-08-12 |
Not clear |
| J K Buitelaar, S H Willemsen-Swinkel. Medication treatment in subjects with autistic spectrum disorders. European child & adolescent psychiatry. vol 9 Suppl 1. 2001-02-22. PMID:11140783. |
pharmacological interventions with serotonin reuptake blockers or with atypical neuroleptics that block both dopamine (d2) and serotonin (5-ht2) receptors seem to offer clinical benefit and merit further study. |
2001-02-22 |
2023-08-12 |
human |
| A R Peirson, J W Heucher. Correlations for serotonin levels and measures of mood in a nonclinical sample. Psychological reports. vol 87. issue 3 Pt 1. 2001-02-22. PMID:11191371. |
hence, platelet 5-ht2 receptor sensitivity is inferred from the concentration of serotonin that is required to produce half maximal intracellular calcium mobilisation (ec50). |
2001-02-22 |
2023-08-12 |
Not clear |
| M Igarashi, T Okuda, T Oh-i, M Kog. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. The Journal of dermatology. vol 27. issue 10. 2001-02-08. PMID:11092268. |
changes in plasma serotonin concentration and acceleration plethysmograms in patients with raynaud's phenomenon after long-term treatment with a 5-ht2 receptor antagonist. |
2001-02-08 |
2023-08-12 |
Not clear |
| M Igarashi, T Okuda, T Oh-i, M Kog. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. The Journal of dermatology. vol 27. issue 10. 2001-02-08. PMID:11092268. |
the pretreatment plasma serotonin concentrations of the study patients were significantly higher than those of the normal controls, but became significantly decreased following 5-ht2 administration. |
2001-02-08 |
2023-08-12 |
Not clear |
| D Centurión, A Sánchez-López, M I Ortiz, P De Vries, P R Saxena, C M Villaló. Mediation of 5-HT-induced internal carotid vasodilatation in GR127935- and ritanserin-pretreated dogs by 5-HT7 receptors. Naunyn-Schmiedeberg's archives of pharmacology. vol 362. issue 2. 2001-02-02. PMID:10961380. |
the vasoconstrictor effects of 5-hydroxytryptamine (5-ht) in the internal carotid bed of anaesthetised dogs with bilateral vagosympathectomy are mainly mediated by both 5-ht1b and 5-ht2 receptors. |
2001-02-02 |
2023-08-12 |
Not clear |
| D Centurión, A Sánchez-López, M I Ortiz, P De Vries, P R Saxena, C M Villaló. Mediation of 5-HT-induced internal carotid vasodilatation in GR127935- and ritanserin-pretreated dogs by 5-HT7 receptors. Naunyn-Schmiedeberg's archives of pharmacology. vol 362. issue 2. 2001-02-02. PMID:10961380. |
the blockade of this vasoconstrictor effect of 5-ht by the combined use of the antagonists, gr127935 (5-ht1b/1d) and ritanserin (5-ht2), unmasks a dose-dependent vasodilator effect of 5-ht, but not of sumatriptan. |
2001-02-02 |
2023-08-12 |
Not clear |
| S Raskin, R Durst, G Katz, J Zisli. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. Journal of clinical psychopharmacology. vol 20. issue 5. 2001-02-02. PMID:11001233. |
olanzapine affinity is related more to serotonin 5-ht2 than to dopamine-2, whereas sulpiride is considered a selective d2 blocker. |
2001-02-02 |
2023-08-12 |
Not clear |
| P B Rosenberg, R B Rosse, B L Schwartz, S I Deutsc. Nefazodone in the adjunctive therapy of schizophrenia: an open-label exploratory study. Clinical neuropharmacology. vol 23. issue 4. 2001-02-02. PMID:11020129. |
compared to conventional antipsychotic medications, atypical antipsychotic medications demonstrate greater central serotonin (5ht2) receptor antagonism than dopamine type 2 (d2) receptor antagonism. |
2001-02-02 |
2023-08-12 |
Not clear |
| M Berk, D J Stein, A Potgieter, C M Maud, C Els, M L Janet, E Viljoe. Serotonergic targets in the treatment of antidepressant induced sexual dysfunction: a pilot study of granisetron and sumatriptan. International clinical psychopharmacology. vol 15. issue 5. 2001-01-18. PMID:10993131. |
while there is some evidence of involvement of the serotonin (5-ht2) receptor subtype in this phenomenon, other serotonergic receptor systems are not well studied. |
2001-01-18 |
2023-08-12 |
Not clear |
| L N Yatham, M Steiner, P F Liddle, I S Shiah, R W Lam, A P Zis, M Coot. A PET study of brain 5-HT2 receptors and their correlation with platelet 5-HT2 receptors in healthy humans. Psychopharmacology. vol 151. issue 4. 2001-01-18. PMID:11026749. |
platelets share many properties with brain serotonergic neurons such as active 5-hydroxytryptamine (5-ht) transport, 5-ht2 receptors, and mitochondrial monoamine oxidase. |
2001-01-18 |
2023-08-12 |
Not clear |
| H Gong, M Rashid, T Nakamura, K Hattori, M Nakazawa, H Kihara, R Yoshimoto, T Nagatom. Inhibitory effects of a newly synthesized 5-HT2 receptor antagonist, AT-1015 (N-[2-[4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidino]-ethyl]-1-for myl-4-piperidinecarboxamide monohydrochloride monohydrate), on contraction and relaxation of pig coronary arteries induced by 5-HT and alpha-methylserotonin: comparison with ketanserin. Biological & pharmaceutical bulletin. vol 23. issue 9. 2001-01-08. PMID:10993215. |
inhibitory effects of a newly synthesized 5-ht2 receptor antagonist, at-1015 (n-[2-[4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)piperidino]-ethyl]-1-for myl-4-piperidinecarboxamide monohydrochloride monohydrate), on contraction and relaxation of pig coronary arteries induced by 5-ht and alpha-methylserotonin: comparison with ketanserin. |
2001-01-08 |
2023-08-12 |
Not clear |
| A Mizuno, M Miya, T Kamei, M Shibata, T Tatsuoka, K Nakanishi, C Takiguchi, T Hidaka, A Yamaki, N Inomat. Studies on antihypertensive agents with antithrombotic activity. 2. Syntheses and pharmacological evaluation of pyrrolo[2,3-c]azepine derivatives. Chemical & pharmaceutical bulletin. vol 48. issue 8. 2000-12-28. PMID:10959576. |
as an extension of our previous investigation, a series of 7-aminoalkylpyrrolo[2,3-c]azepine derivatives was synthesized and evaluated as alpha1-adrenergic- and serotonin 2 (5-ht2)-receptor antagonists, with the aim of finding a novel potent antihypertensive agent with both activities. |
2000-12-28 |
2023-08-12 |
mouse |
| R Ranganathan, S C Cannon, H R Horvit. MOD-1 is a serotonin-gated chloride channel that modulates locomotory behaviour in C. elegans. Nature. vol 408. issue 6811. 2000-12-28. PMID:11100728. |
the neurotransmitter and neuromodulator serotonin (5-ht) functions by binding either to metabotropic g-protein-coupled receptors (for example, 5-ht1, 5-ht2, 5-ht4 to 5-ht7), which mediate 'slow' modulatory responses through numerous second messenger pathways, or to the ionotropic 5-ht3 receptor, a non-selective cation channel that mediates 'fast' membrane depolarizations. |
2000-12-28 |
2023-08-12 |
caenorhabditis_elegans |
| K Taniyama, N Makimoto, A Furuichi, Y Sakurai-Yamashita, Y Nagase, M Kaibara, T Kanemats. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. Journal of gastroenterology. vol 35. issue 8. 2000-12-07. PMID:10955595. |
in this article, we described mainly the 5-ht4 receptor of four subtypes of functional 5-ht receptors, 5-ht1, 5-ht2, 5-ht3, and 5-ht4, recognized in the gastrointestinal tract. |
2000-12-07 |
2023-08-12 |
human |
| R S Mirzoian, A V Topchian, T S Gan'shina, L M Kostochk. [Tropoxin and cerebrovascular effects of serotonin]. Eksperimental'naia i klinicheskaia farmakologiia. vol 63. issue 3. 2000-09-29. PMID:10934590. |
tropoxin, a 5ht2 receptor blocker, completely eliminated these cerebrovascular effects of serotonin. |
2000-09-29 |
2023-08-12 |
rat |
| A Mizuno, A Ogata, T Kamei, M Shibata, T Shimamoto, Y Hayashi, K Nakanishi, C Takiguchi, N Oka, N Inomat. Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds. Chemical & pharmaceutical bulletin. vol 48. issue 5. 2000-09-20. PMID:10823697. |
synthesis and serotonin 2 (5-ht2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds. |
2000-09-20 |
2023-08-12 |
mouse |
| A Mizuno, A Ogata, T Kamei, M Shibata, T Shimamoto, Y Hayashi, K Nakanishi, C Takiguchi, N Oka, N Inomat. Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds. Chemical & pharmaceutical bulletin. vol 48. issue 5. 2000-09-20. PMID:10823697. |
a series of 5-aminoalkylpyrrolo[3,2-c]azepine derivatives was synthesized and their serotonin 2 (5-ht2) receptor antagonist and antiplatelet aggregation activities were evaluated. |
2000-09-20 |
2023-08-12 |
mouse |
| S Oberndorfer, G Saletu-Zyhlarz, B Salet. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology. vol 42. issue 2. 2000-09-15. PMID:10940762. |
novel 5-ht reuptake inhibitors with additional modes of action such as 5-ht2 antagonism (e.g. |
2000-09-15 |
2023-08-12 |
human |
| J K Buitelaar, S H Willemsen-Swinkel. Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatric drugs. vol 2. issue 1. 2000-08-29. PMID:10937459. |
pharmacological interventions with serotonin reuptake inhibitors or with atypical neuroleptics that block both dopamine (d2) and serotonin (5-ht2) receptors seem to offer clinical benefit and merit further study. |
2000-08-29 |
2023-08-12 |
Not clear |